Trial Profile
A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Pimitespib (Primary)
- Indications Gastrointestinal stromal tumours; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Taiho Oncology; Taiho Pharmaceutical
- 21 May 2019 Status changed from active, no longer recruiting to completed.
- 14 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2018 Planned number of patients changed from 250 to 175.